Purpose: To report unusual presentations of type 2A idiopathic macular telangiectasia (IMT). Methods: A retrospective analysis of disease presentation was conducted in 32 patients with type 2A IMT. All patients underwent a complete ophthalmological examination, including spectral domain optical coherence tomography (SD-OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA). Results: Three out of 32 study patients showed the simultaneous presentation of type 2 IMT and other retinal diseases. In the first patient, the ophthalmological examination revealed a proliferative IMT associated with late-onset Stargardt disease. The second patient presented bilateral nonproliferative IMT and chronic serous chorioretinopathy in the left eye. The examination of the third patient revealed basal laminar drusen and soft drusen associated with IMT in both eyes. Conclusions: Type 2 IMT may represent an unusual presentation of Stargardt disease, chronic serous chorioretinopathy and basal laminar drusen. These presentations are most likely coincidental and highlight the importance of FA, ICGA and SD-OCT in the diagnosis and treatment of such cases.

Keywords:
Spectral domain optical coherence tomography, Chronic serous chorioretinopathy, Basal laminar drusen, Fluorescein angiography, Idiopathic macular telangiectasia
1.
Gass JD, Oyakawa RT: Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769-780.
2.
Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993;100:1536-1546.
3.
Gass JDM: Stereoscopic Atlas of Macular Disease, ed 4. St Louis, Mosby, 1997, pp 505-511.
4.
Gaudric A, Ducos de Lahitte G, Cohen SY, Massin P, Haouchine B: Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006;124:1410-1419.
5.
Charbel Issa P, Helb HM, Holz FG, Scholl HP, MacTel Study Group: Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol 2008;145:169-175.
6.
Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B: Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-460.
7.
Querques G, Coscas G, Soubrane G, Souied EH: Type II idiopathic macular telangiectasia and soft confluent drusen. Eur J Ophthalmol 2010;20:466-468.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.